Biotest Aktiengesellschaft Market Cap ($656.94 Million)
Market Cap & Net Worth: Biotest Aktiengesellschaft (BIO3)
Biotest Aktiengesellschaft market cap. Biotest Aktiengesellschaft (XETRA:BIO3) has a market capitalization of $656.94 Million (€561.91 Million) as of November 2, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #10495 globally and #1254 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotest Aktiengesellschaft's stock price €28.40 by its total outstanding shares 19785700 (19.79 Million). Also see BIO3 cash flow metrics for how efficiently the company converts equity into cash flow.
Biotest Aktiengesellschaft Market Cap History (2015–2025)
Biotest Aktiengesellschaft market cap history from 2015 to 2025. Data shows growth from $350.89 Million to $656.94 Million (4.47% CAGR). Check BIO3 stock price for real-time trading data and today's change.
Biotest Aktiengesellschaft Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotest Aktiengesellschaft's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BIO3 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.86x
Biotest Aktiengesellschaft's market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
23.66x
Biotest Aktiengesellschaft's market cap is 23.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $350.89 Million | $589.60 Million | -$82.50 Million | 0.60x | N/A |
| 2016 | $305.91 Million | $553.10 Million | -$45.80 Million | 0.55x | N/A |
| 2017 | $462.91 Million | $378.10 Million | -$3.50 Million | 1.22x | N/A |
| 2018 | $539.42 Million | $400.30 Million | $181.70 Million | 1.35x | 2.97x |
| 2019 | $471.41 Million | $419.10 Million | -$4.70 Million | 1.12x | N/A |
| 2020 | $647.44 Million | $484.20 Million | -$31.40 Million | 1.34x | N/A |
| 2021 | $890.59 Million | $515.60 Million | -$63.40 Million | 1.73x | N/A |
| 2022 | $785.35 Million | $516.10 Million | -$31.70 Million | 1.52x | N/A |
| 2023 | $716.05 Million | $684.60 Million | $127.00 Million | 1.05x | 5.64x |
| 2024 | $624.55 Million | $726.20 Million | $26.40 Million | 0.86x | 23.66x |
Competitor Companies of BIO3 by Market Capitalization
Companies near Biotest Aktiengesellschaft in the global market cap rankings as of November 2, 2026. Also see Biotest Aktiengesellschaft total assets for a full breakdown of the balance sheet.
Key companies related to Biotest Aktiengesellschaft by market ranking:
- Anhui Zhonghuan Environmental Protection Technology Co Ltd (SHE:300692): Ranked #10486 globally with a market cap of $658.23 Million USD ( CN¥4.50 Billion CNY).
- Contrel Technology Co Ltd (TWO:8064): Ranked #10487 globally with a market cap of $657.97 Million USD ( NT$20.88 Billion TWD).
- Chapters Group AG (XETRA:CHG): Ranked #10496 globally with a market cap of $656.80 Million USD ( €561.80 Million EUR).
- Zhejiang Yonggui Electric Equipment Co Ltd (SHE:300351): Ranked #10497 globally with a market cap of $656.74 Million USD ( CN¥4.49 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #10486 | Anhui Zhonghuan Environmental Protection Technology Co Ltd | SHE:300692 | $658.23 Million | CN¥8.00 |
| #10487 | Contrel Technology Co Ltd | TWO:8064 | $657.97 Million | NT$113.00 |
| #10496 | Chapters Group AG | XETRA:CHG | $656.80 Million | €45.75 |
| #10497 | Zhejiang Yonggui Electric Equipment Co Ltd | SHE:300351 | $656.74 Million | CN¥11.54 |
Market Capitalization of Biotest Aktiengesellschaft (2015–2025)
Market capitalization of Biotest Aktiengesellschaft from 2015 to today. Between 2015 and today, Biotest Aktiengesellschaft's market cap moved from $350.89 Million to $ 656.94 Million, with a yearly change of 4.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €656.94 Million | +5.19% |
| 2024 | €624.55 Million | -12.78% |
| 2023 | €716.05 Million | -8.82% |
| 2022 | €785.35 Million | -11.82% |
| 2021 | €890.59 Million | +37.56% |
| 2020 | €647.44 Million | +37.34% |
| 2019 | €471.41 Million | -12.61% |
| 2018 | €539.42 Million | +16.53% |
| 2017 | €462.91 Million | +51.32% |
| 2016 | €305.91 Million | -12.82% |
| 2015 | €350.89 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 5th, 2026 the market cap of Biotest Aktiengesellschaft was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $656.94 Million USD |
| MoneyControl | $656.94 Million USD |
| MarketWatch | $656.94 Million USD |
| marketcap.company | $656.94 Million USD |
| Reuters | $656.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more